Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

XPhyto to Announce PCR Test Kit Final Validation Results

It could be the Holy Grail of COVID-19 testing. Remarkably, a small Canadian life sciences company, XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) is becoming a front-runner in the race to bring this breakthrough technology to market – starting with Germany. This ref...
Marc Davis | November 26, 2020 |

XPhyto Announces a PCR Testing Breakthrough

It’s the technological breakthrough that the world has been waiting for. A small Canadian life sciences company, XPhyto Therapeutics Corp. ( CSE:XPHY ) (FSE:4XT), has just announced its ability to significantly speed up testing for COVID-19 in an...
Marc Davis | December 17, 2020 |

XPhyto Therapeutics: Are they Selling the Solution to Germany’s Rapid Testing Crisis?

The Germans call it COVID-19 “rapid testing mania”. But like most manias, it has opened up a Pandora’s box of problems. As the speed of the vaccine rollout program falters in Europe, on-the-spot antigen testing continues to be the ...
Marc Davis | June 2, 2021 |

This Is What First Lagarde’s Speech Means for Gold

Overbought and oversold Learning to master the markets is like drinking from a fire hose. This does not change, no matter at what stage of the game you are. The vastness of possibilities and the challenges of psychology are endless. Therefore the only way of mane...
Korbinian Koller | December 6, 2019 |

Introducing the ‘Better Quality, Better Serviced” Video Conferencing Platform

(Click image to play video) Simplified video conferencing across any device means exceptional usability. Enhanced security settings ensure continuous meeting time, encryption, role-based security and password protection. Introducing Fuzion – providing one integ...
Dave Jackson | November 26, 2020 |

Invitae Corp. Enters into Definitive Agreement to Acquire ArcherDX

Shares of Invitae Corp. traded 40% higher after the company reported it will acquire ArcherDX in a combination cash and stock deal valued at around $1.4 billion. Advanced medical genetics company Invitae Corp. (NVTA:NYSE) and genomics analysis firm ArcherDX today...
Streetwise Reports | June 23, 2020 |

XPhyto: Why Rapid PCR Testing is Here to Stay

Regular coronavirus testing is destined to become the norm for many years to come, regardless of how many people get vaccinated against COVID-19. So says Hugh Rogers, the CEO of XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) ( OTC: XPHYF ) , a Canadian life scie...
Marc Davis | April 22, 2021 |

A Life Sciences Project Accelerator Kicks into High Gear

XPhyto Therapeutics Corp. ( CSE: XPHY ) (FSE: 4XT) (OTC: XPHYF) has been a hot story lately, especially in Germany, due to its recent commercialization of a super-fast PCR test kit for definitively diagnosing COVID-19 infections in point-of-care settings. The company rec...
Marc Davis | May 10, 2021 |

Baudax Shares Rise as FDA Approves NDA for Its Non-Opioid Pain Medication

Shares of Baudax Bio traded more than 20% higher and set a new 52-week high price after reporting that the FDA approved the company's non-opioid ANJESO™ drug for management of moderate to severe pain. Specialty pharmaceutical company Baudax Bio Inc. (BXRX:N...
Streetwise Reports | February 24, 2020 |

XPhyto: Buyouts, Biosensors and a Booming Business

Test, test, test! It’s the World Health Organization’s battle cry in the global war against COVID-19 and other coronaviruses – including future outbreaks. And it is not getting any less resonant as new variants continue to cause ha...
Marc Davis | August 3, 2021 |
1 2 3 4